静注用鉄剤の市場規模、シェア、動向分析レポート：製品別、用途別、地域別、セグメント予測、2024年～2030年

静注用鉄剤市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の静注用鉄剤市場規模は2024～2030年にかけてCAGR 9.2%で拡大し、2030年には56億2,000万米ドルに達する見込みです。

予測期間中、業界の競争はより高いレベルで維持されると予想されます。同市場は、収益シェアの大半を世界企業が占めています。さらに、成長機会が新たな参入企業を引き付け、競争企業間の敵対関係をさらに強化しています。市場はセグメント化されており、大手企業はより大きなシェアを獲得するために、戦略的提携、買収、新薬の上市など、広範な成長戦略を採用しています。

感染症による高い疾病負担は、栄養不良と相まって、この地域の小児の貧血の主要原因の一つとなっています。新型コロナウイルスの大流行も、重症患者の貧血を増加させ、場合によっては低酸素症を引き起こしています。このため、世界中で貧血治療用の鉄剤の需要がさらに高まっています。

貧血の有病率の増加は、様々な婦人科疾患や消化器疾患にも起因しており、静脈内治療の世界の普及を促進しています。例えば、貧血の全体的な有病率は、非妊娠女性で29.6%、同年齢層の妊娠女性で36.5%です。医療予算の増加と投資の増加により、市場は予測期間中に大きく成長すると予想されます。

経口鉄剤の欠点である胃痛、便秘、食欲不振、吐き気、嘔吐などの消化器系の問題は、患者が静脈注射剤を好む理由となっています。静注用鉄剤は、体内への鉄の取り込みを増加させ、赤血球造血刺激因子（ESA）の働きを促進し、貧血状態を改善することが示されています。その他の利点としては、心臓の健康が保たれること、透析患者、特に血液透析を受けている患者が使用できることなどが挙げられます。

静注用鉄剤市場レポートハイライト

• カルボキシマルトース鉄は、その用途の増加、副作用の少なさと相まって優れた性能、コストの削減により、2023年に静脈内鉄剤業界を支配しました。
• スクロース鉄は2023年に市場で大きなシェアを占めました。重篤なアレルギー反応の発生率が低いことが、これらの薬剤の採用率を高めています。
• CKDとCKD関連鉄欠乏性貧血症例の有病率の増加により、慢性腎臓病セグメントが2023年に最大のシェアを占めました。
• 北米は、点滴薬に対する高い需要と、消化器疾患、がん、CKDの有病率の増加により、2023年に最大の地域シェアを占めました。
• アジア太平洋は、アンメットニーズの高まり、医療費の増加、定評ある世界企業の現地進出を背景に、推定・予測期間中に最も急成長するとみられます。
• 主要参入企業には、AbbVie Inc.、AMAG Pharmaceuticals（Covis Pharma）、第一三共株式会社、Sanofi、Vifor Pharma Management Ltd.（CSL）、PHARMAC、Pharmaceuticals Inc.（CSL）、PHARMACOSMOS A/S、Zydus Groupなどです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブ概要

第3章 静脈内鉄剤市場-業界展望

• 市場系統の展望
• 市場力学
• ポーターのファイブフォース分析
• PESTLE分析
• COVID-19の影響分析

第4章 静脈内鉄剤市場-セグメント分析、製品別、2018～2030年（100万米ドル）

• 静脈内鉄剤市場：製品変動分析
• 製品別
  • 鉄デキストラン
  • 鉄スクロース
  • カルボキシマルトース鉄
  • その他

第5章 静脈内鉄剤市場-セグメント分析、用途別、2018～2030年（100万米ドル）

• 静脈内鉄剤市場：用途変動分析
• 用途別

第6章 静脈内鉄剤市場：地域推定・動向分析

• 静脈内鉄剤市場：地域別展望
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第7章 競合情勢

• 企業分類
• 戦略マッピング
  • 新製品発売
  • パートナーシップ
  • 取得
  • コラボレーション
  • 資金調達
• 主要企業の市場シェア分析、2022年
• 企業プロファイル
  • Allergan, Inc.
  • AMAG Pharmaceuticals. Inc.
  • Daiichi Sankyo Company, Ltd.
  • Sanofi
  • Fresenius Medical Care AG &Co.
  • Vifor Pharma Management Ltd.
  • Pharmacosmos A/S
  • Rockwell Medical, Inc.

第8章 結論

List of Tables

• Table 1 List of key distributors and channel partners
• Table 2 List of key emerging companies'/technology disruptors/innovators
• Table 3 North America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
• Table 4 North America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 5 North America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 6 U.S. intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 7 U.S. intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 8 Canada intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 9 Canada intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 10 Europe intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
• Table 11 Europe intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 12 Europe intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 13 Germany intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 14 Germany intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 15 UK intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 16 UK intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 17 France intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 18 France intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 19 Spain intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 20 Spain intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 21 Italy intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 22 Italy intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 23 Denmark intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 24 Denmark intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 25 Sweden intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 26 Sweden intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 27 Norway intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 28 Norway intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 29 Asia Pacific intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
• Table 30 Asia Pacific intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 31 Asia Pacific intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 32 China intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 33 China intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 34 India intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 35 India intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 36 Japan intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 37 Japan intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 38 South Korea intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 39 South Korea intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 40 Thailand intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 41 Thailand intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 42 Australia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 43 Australia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 44 Latin America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
• Table 45 Latin America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 46 Latin America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 47 Brazil intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 48 Brazil intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 49 Mexico intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 50 Mexico intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 51 Argentina intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 52 Argentina intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 53 MEA intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
• Table 54 MEA intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 55 MEA intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 56 South Africa intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 57 South Africa intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 58 Saudi Arabia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 59 Saudi Arabia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 60 UAE intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 61 UAE intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
• Table 62 Kuwait intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
• Table 63 Kuwait intravenous iron drugs market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Intravenous iron drugs market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation and validation
• Fig. 9 Commodity flow approach
• Fig. 10 Market snapshot (USD Million)
• Fig. 11 Segment snapshot (product & application)
• Fig. 12 Competitive snapshot
• Fig. 13 Parent market (USD Billion)
• Fig. 14 Market dynamics
• Fig. 15 Prevalence of cancer, by type, in 2020 (%)
• Fig. 16 Porter's five forces analysis
• Fig. 17 PESTLE analysis
• Fig. 18 Intravenous iron drugs market: Product outlook and key takeaways
• Fig. 19 Intravenous iron drugs market: Product movement analysis
• Fig. 20 Iron dextran market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Iron sucrose market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 FCM market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Intravenous iron drugs market: Application outlook and key takeaways
• Fig. 25 Intravenous iron drugs market: Application movement analysis
• Fig. 26 Chronic kidney disease market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Inflammatory bowel disease market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Incidence of key cancer types that increase the risk of anemia, 2020 (in thousand)
• Fig. 30 Other diseases market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Intravenous iron drugs market revenue, by region, 2023 & 2030 (USD Million)
• Fig. 32 Regional marketplace: Key takeaways (1/2)
• Fig. 33 Regional marketplace: Key takeaways (2/2)
• Fig. 34 North America intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Key country dynamics
• Fig. 36 U.S. intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Cancer incidence, 2022 and 2030
• Fig. 38 Key country dynamics
• Fig. 39 Canada intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Cancer incidence, 2018 - 2030
• Fig. 41 Europe intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Key country dynamics
• Fig. 43 UK intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 Cancer incidence, 2018 - 2030
• Fig. 45 Key country dynamics
• Fig. 46 Germany intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 47 Cancer incidence, 2018 - 2030
• Fig. 48 Key country dynamics
• Fig. 49 France intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 50 Cancer incidence, 2018 - 2030
• Fig. 51 Key country dynamics
• Fig. 52 Italy intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 53 Cancer incidence, 2018 - 2030
• Fig. 54 Key country dynamics
• Fig. 55 Spain intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 56 Cancer incidence, 2018 - 2030
• Fig. 57 Key country dynamics
• Fig. 58 Denmark intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 59 Target disease prevalence
• Fig. 60 Key country dynamics
• Fig. 61 Sweden intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 62 Five most common cancers in Sweden
• Fig. 63 Key country dynamics
• Fig. 64 Norway intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 65 Number of new cancer cases in 2020, both sexes, all ages
• Fig. 66 Rest of Europe market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 67 Asia Pacific intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 68 Key country dynamics
• Fig. 69 Japan intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 70 Number of new cases in 2020, both sexes, all ages
• Fig. 71 Key country dynamics
• Fig. 72 China intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 73 Cancer incidence, 2018 to 2030
• Fig. 74 Key country dynamics
• Fig. 75 India intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 76 Cancer incidence, 2018 to 2030
• Fig. 77 Key country dynamics
• Fig. 78 Australia intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 79 Cancer incidence, 2018 to 2030
• Fig. 80 Key country dynamics
• Fig. 81 Thailand intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 82 Cancer incidence, 2020 to 2030
• Fig. 83 Key country dynamics
• Fig. 84 South Korea intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 85 Cancer incidence 2018 to 2030
• Fig. 86 Rest of Asia Pacific intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 87 Latin America intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Key country dynamics
• Fig. 89 Brazil intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Estimated number of new cancer cases in Brazil
• Fig. 91 Key country dynamics
• Fig. 92 Mexico intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Estimated number of new cancer cases in Mexico
• Fig. 94 Key country dynamics
• Fig. 95 Argentina intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 96 Estimated number of new cancer cases in Argentina
• Fig. 97 Rest of Latin America intravenous iron drugs market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 98 MEA intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 99 Key country dynamics
• Fig. 100 South Africa intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 101 Cancer prevalence -2018 - 2030
• Fig. 102 Key country dynamics
• Fig. 103 Saudi Arabia intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 104 Cancer prevalence - 2018 - 2030
• Fig. 105 Key country dynamics
• Fig. 106 UAE intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 107 Cancer prevalence-2018 - 2030
• Fig. 108 Key country dynamics
• Fig. 109 Kuwait intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 110 Target disease prevalence
• Fig. 111 Rest of MEA intravenous iron drugs market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 112 Market participant categorization
• Fig. 113 Company market share analysis, 2023
• Fig. 114 Strategic framework

Intravenous Iron Drugs Market Growth & Trends:

The global intravenous iron drugs market size is expected to reach USD 5.62 billion by 2030, expanding at a CAGR of 9.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Industry rivalry is expected to remain at a higher level over the forecast period. The market is dominated by global players accounting for most of the revenue share. Moreover, growing opportunities attract new players, which further augments the competitive rivalry. The market is fragmented and major players are involved in adopting extensive growth strategies such as entering strategic alliances, acquisitions, and new drug launches to capture a larger share.

The high disease burden of infectious diseases, coupled with poor nutrition, is one of the major causes of anemia among children in this region. The novel coronavirus pandemic has also increased anemia in severely affected patients, causing hypoxia in some cases. This has further increased the demand for intravenous iron drugs for the treatment of anemia across the globe.

The increase in the prevalence of anemia can also be attributed to various gynecological and gastrointestinal disorders, facilitating an increasing uptake of IV treatment globally. For instance, the overall prevalence of anemia is 29.6% in nonpregnant women and 36.5% in pregnant women of the same age group. With growing healthcare budgets and increasing investment, the market is anticipated to grow significantly during the forecast period.

Drawbacks of oral iron drugs such as digestive problems such as stomach aches, constipation, loss of appetite, nausea, and vomiting are reasons for patients to prefer intravenous drugs. The use of intravenous iron drugs has been shown to bring about increased iron adoption by the body, facilitating Erythropoiesis-stimulating Agents (ESAs) to function in an enhanced manner to improve the anemic condition. Other advantages are the preservation of heart health and the ability to be used by dialysis patients, especially those undergoing hemodialysis.

Intravenous Iron Drugs Market Report Highlights:

• Ferric carboxymaltose dominated the intravenous iron drugs industry in 2023 due to its increasing application, superior performance coupled with fewer adverse effects, and reduced cost
• Iron sucrose held a significant share of the market in 2023. A low rate of severe allergic reactions has increased the adoption rate of these drugs
• The chronic kidney disease segment held the largest share in 2023, due to the increasing prevalence of CKD and CKD-associated iron deficiency anemia cases
• North America held the largest regional share in 2023 due to the high demand for intravenous drugs and the increasing prevalence of GI disorders, cancer, and CKD
• Asia Pacific is estimated to exhibit the fastest growth over the forecast period attributed to growing unmet patient needs, increasing healthcare expenditure, and the local presence of established global players
• Key players include AbbVie Inc.; AMAG Pharmaceuticals (Covis Pharma); Daiichi Sankyo Company, Ltd.; Sanofi; Vifor Pharma Management Ltd. (CSL); PHARMACOSMOS A/S; Zydus Group

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation & Scope
  • 1.1.1 Regional Scope
  • 1.1.2 Market Definitions
  • 1.1.3 Estimates and Forecast Timeline
• 1.2 Objectives
  • 1.2.1 Objective - 1
  • 1.2.2 Objective - 2
  • 1.2.3 Objective - 3
• 1.3 Research Methodology
• 1.4 Information Procurement
  • 1.4.1 Purchased Database
  • 1.4.2 GVR's Internal Database
  • 1.4.3 Secondary Sources
  • 1.4.4 Primary research
  • 1.4.5 Sample size for the study on Intravenous Iron Drugs Market:
• 1.5 Information or Data Analysis
  • 1.5.1 Data Analysis Models
• 1.6 Market Formulation and Validation
• 1.7 Market Model
  • 1.7.1 Market study, by Company Market Share
  • 1.7.2 Commodity Flow Analysis
    • 1.7.2.1 Approach 1: Commodity Flow Approach
    • 1.7.2.2 Approach 2: Country Wise Market Estimation Using Bottom-up Approach
  • 1.7.3 Regional analysis
• 1.8 Research Assumptions
• 1.9 List of Secondary Sources
• 1.10 List of Abbreviations

Chapter 2 EXECUTIVE SUMMARY

• 2.1 Market Snapshot, 2023
• 2.2 Segment Snapshot
• 2.3 Competitive Snapshot

Chapter 3 Intravenous Iron Drugs Market - Industry Outlook

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market
  • 3.1.2 Related/Ancillary Market Outlook
    • 3.1.2.1 Inflammatory Bowel Disease Treatment Market
    • 3.1.2.2 Anemia Treatment Market
• 3.2 Market Dynamics
  • 3.2.1 Market Drivers
    • 3.2.1.1 Increasing prevalence of target diseases
    • 3.2.1.2 Rising prevalence of iron deficiency anemia
    • 3.2.1.3 Advantages of intravenous iron drugs
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 Adverse effects associated with iron drugs
    • 3.2.2.2 Increasing approvals of oral iron drugs
• 3.3 PORTER'S Five Forces Analysis
• 3.4 PESTLE Analysis
• 3.5 COVID-19 Impact Analysis

Chapter 4 Intravenous Iron Drugs Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)

• 4.1 Intravenous Iron Drugs Market: Product Movement Analysis
• 4.2 Intravenous Iron Drugs Market Estimates & Forecast, by Product (USD Million)
  • 4.2.1 Iron Dextran
  • 4.2.2 Iron Sucrose
  • 4.2.3 Ferric Carboxymaltose
  • 4.2.4 Others

Chapter 5 Intravenous Iron Drugs Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)

• 5.1 Intravenous Iron Drugs Market: Application Movement Analysis
• 5.2 Intravenous Iron Drugs Market Estimates & Forecast, by Application (USD Million)
  • 5.2.1 Chronic Kidney Disease
  • 5.2.2 Inflammatory Bowel Disease
  • 5.2.3 Cancer
  • 5.2.4 Other Diseases

Chapter 6 Intravenous Iron Drugs Market: Regional Estimates and Trend Analysis

• 6.1 Intravenous Iron Drugs Market: Regional Outlook
• 6.2 North America
  • 6.2.1 North America Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.2.2 U.S.
    • 6.2.2.1 Key Country Dynamics
    • 6.2.2.2 U.S. Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2.3 Target Disease Prevalence
    • 6.2.2.4 Market & Competitive Scenario
    • 6.2.2.5 Regulatory Framework
    • 6.2.2.6 Reimbursement Scenario
  • 6.2.3 Canada
    • 6.2.3.1 Key Country Dynamics
    • 6.2.3.2 Canada Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3.3 Target Disease Prevalence
    • 6.2.3.4 Market & Competitive Scenario
    • 6.2.3.5 Regulatory Framework
    • 6.2.3.6 Reimbursement Scenario
• 6.3 Europe
  • 6.3.1 Europe Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.3.2 UK
    • 6.3.2.1 Key Country Dynamics
    • 6.3.2.2 UK Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2.3 Target Disease Prevalence
    • 6.3.2.4 Market & Competitive Scenario
    • 6.3.2.5 Regulatory Framework
    • 6.3.2.6 Reimbursement Scenario
  • 6.3.3 Germany
    • 6.3.3.1 Key Country Dynamics
    • 6.3.3.2 Germany Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3.3 Target Disease Prevalence
    • 6.3.3.4 Market & Competitive Scenario
    • 6.3.3.5 Regulatory Framework
    • 6.3.3.6 Reimbursement Scenario
  • 6.3.4 France
    • 6.3.4.1 Key Country Dynamics
    • 6.3.4.2 France Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4.3 Target Disease Prevalence
    • 6.3.4.4 Market & Competitive Scenario
    • 6.3.4.5 Regulatory Framework
    • 6.3.4.6 Reimbursement Scenario
  • 6.3.5 Italy
    • 6.3.5.1 Key Country Dynamics
    • 6.3.5.2 Italy Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5.3 Target Disease Prevalence
    • 6.3.5.4 Market & Competitive Scenario
    • 6.3.5.5 Regulatory Framework
    • 6.3.5.6 Reimbursement Scenario
  • 6.3.6 Spain
    • 6.3.6.1 Key Country Dynamics
    • 6.3.6.2 Spain Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6.3 Target Disease Prevalence
    • 6.3.6.4 Market & Competitive Scenario
    • 6.3.6.5 Regulatory Framework
    • 6.3.6.6 Reimbursement Scenario
  • 6.3.7 Denmark
    • 6.3.7.1 Key Country Dynamics
    • 6.3.7.2 Denmark Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7.3 Target Disease Prevalence
    • 6.3.7.4 Market & Competitive Scenario
    • 6.3.7.5 Regulatory Framework
    • 6.3.7.6 Reimbursement Scenario
  • 6.3.8 Sweden
    • 6.3.8.1 Key Country Dynamics
    • 6.3.8.2 Sweden Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8.3 Target Disease Prevalence
    • 6.3.8.4 Market & Competitive Scenario
    • 6.3.8.5 Regulatory Framework
    • 6.3.8.6 Reimbursement Scenario
  • 6.3.9 Norway
    • 6.3.9.1 Key Country Dynamics
    • 6.3.9.2 Norway Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9.3 Target Disease Prevalence
    • 6.3.9.4 Market & Competitive Scenario
    • 6.3.9.5 Regulatory Framework
    • 6.3.9.6 Reimbursement Scenario
    • 6.3.9.7 Rest of Europe Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)s
• 6.4 Asia Pacific
  • 6.4.1 Asia Pacific Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2 Japan
    • 6.4.2.1 Key Country Dynamics
    • 6.4.2.2 Japan Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2.3 Target Disease Prevalence
    • 6.4.2.4 Market & Competitive Scenario
    • 6.4.2.5 Regulatory Framework
    • 6.4.2.6 Reimbursement Scenario
  • 6.4.3 China
    • 6.4.3.1 Key Country Dynamics
    • 6.4.3.2 China Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3.3 Target Disease Prevalence
    • 6.4.3.4 Market & Competitive Scenario
    • 6.4.3.5 Regulatory Framework
    • 6.4.3.6 Reimbursement Scenario
  • 6.4.4 India
    • 6.4.4.1 Key Country Dynamics
    • 6.4.4.2 India Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4.3 Target Disease Prevalence
    • 6.4.4.4 Market & Competitive Scenario
    • 6.4.4.5 Regulatory Framework
    • 6.4.4.6 Reimbursement Scenario
  • 6.4.5 Australia
    • 6.4.5.1 Key Country Dynamics
    • 6.4.5.2 Australia Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5.3 Target Disease Prevalence
    • 6.4.5.4 Market & Competitive Scenario
    • 6.4.5.5 Regulatory Framework & Reimbursement Scenario
  • 6.4.6 Thailand
    • 6.4.6.1 Key Country Dynamics
    • 6.4.6.2 Thailand Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6.3 Target Disease Prevalence
    • 6.4.6.4 Market & Competitive Scenario
    • 6.4.6.5 Regulatory Framework
    • 6.4.6.6 Reimbursement Scenario
  • 6.4.7 South Korea
    • 6.4.7.1 Key Country Dynamics
    • 6.4.7.2 South Korea Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7.3 Target Disease Prevalence
    • 6.4.7.4 Market & Competitive Scenario
    • 6.4.7.5 Regulatory Framework/Reimbursement Scenario
    • 6.4.7.6 Rest of Asia Pacific Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5 Latin America
  • 6.5.1 Latin America Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2 Brazil
    • 6.5.2.1 Key Country Dynamics
    • 6.5.2.2 Brazil Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2.3 Target Disease Prevalence
    • 6.5.2.4 Market & Competitive Scenario
    • 6.5.2.5 Regulatory Framework
    • 6.5.2.6 Reimbursement Scenario
  • 6.5.3 Mexico
    • 6.5.3.1 Key Country Dynamics
    • 6.5.3.2 Mexico Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3.3 Target Disease Prevalence
    • 6.5.3.4 Market & Competitive Scenario
    • 6.5.3.5 Regulatory Framework
    • 6.5.3.6 Reimbursement Scenario
  • 6.5.4 Argentina
    • 6.5.4.1 Key Country Dynamics
    • 6.5.4.2 Argentina Intravenous Iron Drugs Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.4.3 Target Disease Prevalence
    • 6.5.4.4 Market & Competitive Scenario
    • 6.5.4.5 Regulatory Framework
    • 6.5.4.6 Reimbursement Scenario
    • 6.5.4.7 Rest of Latin America Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.6 MEA
  • 6.6.1 MEA Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million
  • 6.6.2 South Africa
    • 6.6.2.1 Key Country Dynamics
    • 6.6.2.2 South Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2.3 Target Disease Prevalence
    • 6.6.2.4 Market & Competitive Scenario
    • 6.6.2.5 Regulatory Framework
    • 6.6.2.6 Reimbursement Scenario
  • 6.6.3 Saudi Arabia
    • 6.6.3.1 Key Country Dynamics
    • 6.6.3.2 Saudi Arabia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3.3 Target Disease Prevalence
    • 6.6.3.4 Market & Competitive Scenario
    • 6.6.3.5 Regulatory Framework
    • 6.6.3.6 Reimbursement Scenario
  • 6.6.4 UAE
    • 6.6.4.1 Key Country Dynamics
    • 6.6.4.2 UAE Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4.3 Target Disease Prevalence
    • 6.6.4.4 Market & Competitive Scenario
    • 6.6.4.5 Regulatory Framework
    • 6.6.4.6 Reimbursement Scenario
  • 6.6.5 Kuwait
    • 6.6.5.1 Key Country Dynamics
    • 6.6.5.2 Kuwait Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5.3 Target Disease Prevalence
    • 6.6.5.4 Market & Competitive Scenario
    • 6.6.5.5 Regulatory Framework
    • 6.6.5.6 Reimbursement Scenario
    • 6.6.5.7 Rest of MEA Intravenous Iron Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7 Competitive Landscape

• 7.1 Company Categorization
• 7.2 Strategy Mapping
  • 7.2.1 New Product Launch
  • 7.2.2 Partnerships
  • 7.2.3 Acquisition
  • 7.2.4 Collaboration
  • 7.2.5 Funding
• 7.3 Key Company Market Share Analysis, 2022
• 7.4 Company Profiles
  • 7.1.1 Allergan, Inc.
    • 7.1.1.1 Company overview
    • 7.1.1.2 Financial performance
    • 7.1.1.3 Product benchmarking
    • 7.1.1.4 Strategic initiatives
  • 7.1.2 AMAG Pharmaceuticals. Inc.
    • 7.1.2.1 Company overview
    • 7.1.2.2 Financial performance
    • 7.1.2.3 Product benchmarking
    • 7.1.2.4 Strategic initiatives
  • 7.1.3 Daiichi Sankyo Company, Ltd.
    • 7.1.3.1 Company overview
    • 7.1.3.2 Financial performance
    • 7.1.3.3 Product benchmarking
    • 7.1.3.4 Strategic initiatives
  • 7.1.4 Sanofi
    • 7.1.4.1 Company overview
    • 7.1.4.2 Financial performance
    • 7.1.4.3 Product benchmarking
    • 7.1.4.4 Strategic initiatives
  • 7.1.5 Fresenius Medical Care AG & Co.
    • 7.1.5.1 Company overview
    • 7.1.5.2 Financial performance
    • 7.1.5.3 Product benchmarking
    • 7.1.5.4 Strategic initiatives
  • 7.1.6 Vifor Pharma Management Ltd.
    • 7.1.6.1 Company overview
    • 7.1.6.2 Financial performance
    • 7.1.6.3 Product benchmarking
    • 7.1.6.4 Strategic initiatives
  • 7.1.7 Pharmacosmos A/S
    • 7.1.7.1 Company overview
    • 7.1.7.2 Financial performance
    • 7.1.7.3 Product benchmarking
    • 7.1.7.4 Strategic initiatives
  • 7.1.8 Rockwell Medical, Inc.
    • 7.1.7.1 Company overview
    • 7.1.7.2 Financial performance
    • 7.1.7.3 Product benchmarking
    • 7.1.7.4 Strategic initiatives

Chapter 8 Conclusion